BET bromodomain inhibition enhances T cell persistence and function in adoptive immunotherapy models

MLA

Kagoya, Yuki, et al. “BET Bromodomain Inhibition Enhances T Cell Persistence and Function in Adoptive Immunotherapy Models.” Journal of Clinical Investigation, Sept. 2016, p. 3479. EBSCOhost, https://doi.org/10.1172/JCI86437.

APA

Kagoya, Y., Nakatsugawa, M., Yamashita, Y., Ochi, T., Guo, T., Anczurowski, M., Saso, K., Butler, M. O., Arrowsmith, C. H., & Hirano, N. (2016). BET bromodomain inhibition enhances T cell persistence and function in adoptive immunotherapy models. Journal of Clinical Investigation, 3479. https://doi.org/10.1172/JCI86437

Chicago

Kagoya, Yuki, Munehide Nakatsugawa, Yuki Yamashita, Toshiki Ochi, Tingxi Guo, Mark Anczurowski, Kayoko Saso, Marcus O. Butler, Cheryl H. Arrowsmith, and Naoto Hirano. 2016. “BET Bromodomain Inhibition Enhances T Cell Persistence and Function in Adoptive Immunotherapy Models.” Journal of Clinical Investigation, September, 3479. doi:10.1172/JCI86437.